ライフサイエンスコーパス: angle-closure glaucoma

1 te detection of patients at risk for primary angle closure glaucoma.

2 with primary open angle glaucoma or primary angle closure glaucoma.

3 omy should be considered in the treatment of angle closure glaucoma.

4 ns/eye volume ratio, and a high incidence of angle-closure glaucoma.

5 nd hypermetropic refractive error on primary angle-closure glaucoma.

6 hway might be involved in biology of primary angle-closure glaucoma.

7 tive effect for both open-angle glaucoma and angle-closure glaucoma.

8 broad categories of glaucoma, open-angle and angle-closure glaucoma.

9 rter of 2023, which included 1629 reports of angle-closure glaucoma.

10 is and hypermetropia confer risk for primary angle-closure glaucoma.

11 origin are the main risk factors for primary angle-closure glaucoma.

12 55 had primary angle closure and 263 primary angle-closure glaucoma.

13 ular pressure 30 mm Hg or greater or primary angle-closure glaucoma.

14 0% (n = 148) with OAG and 1.0% (n = 16) with angle-closure glaucoma.

15 hat antidepressants may increase the risk of angle-closure glaucoma.

16 il dilation is a known risk factor for acute angle-closure glaucoma.

17 re defined according to the first coding for angle-closure glaucoma.

18 ain complications being severe hyperopia and angle-closure glaucoma.

19 r 2013 on the topics open-angle glaucoma and angle-closure glaucoma.

20 rior chamber angles that predisposed them to angle-closure glaucoma.

21 subjects (0.3%, 95% CI, 0.1-0.4) had primary angle-closure glaucoma.

22 utic strategy for certain types of secondary angle-closure glaucoma.

23 eliminate any pupillary block due to primary angle-closure glaucoma.

24 wo forms of glaucoma: open-angle glaucoma or angle-closure glaucoma.

25 NNia substrain of mouse (DBA) with inherited angle-closure glaucoma.

26 omic variations and underlying mechanisms in angle-closure glaucoma.

27 primary open-angle glaucoma (55.9%), chronic angle-closure glaucoma (10.8%), neovascular glaucoma (9.

28 spondents (14.6%; 95% CI, 9.9%-19.3%), acute angle-closure glaucoma; 11 of 216 respondents (5.1%; 95%

29 n-angle glaucoma was more common (86 %) than angle-closure glaucoma (14 %).

30 4%), failure to diagnose or mismanagement of angle-closure glaucoma (18.5%), adverse drug effects (14

31 e interval [CI]: 9%-14%) is more common than angle-closure glaucoma (7%; 95% CI: 3%-13%).

32 e Lymphoblastic Leukemia who developed acute angle closure glaucoma (AACG) following daratumumab infu

33 eyes of 154 patients consisting of 40 acute angle-closure glaucoma (AACG) eyes, 40 fellow eyes of AA

34 onditions: retinal detachment (RD) and acute angle-closure glaucoma (AACG).

35 ), secondary open angle glaucoma (SOAG), and angle closure glaucoma (ACG).

36 Recent studies underscore the importance of angle-closure glaucoma (ACG) as a cause of world blindne

37 gnosed in 3.1% (95% CI = 2.5, 3.8%), primary angle-closure glaucoma (ACG) in 0.59% (95% CI = 0.35, 0.

38 nterior chamber (AC) depth and the attack of angle-closure glaucoma (ACG) in eyes with the recent ons

39 Angle-closure glaucoma (ACG) is a subset of glaucoma aff

40 Angle-closure glaucoma (ACG) occurring during those flig

41 with mitomycin C (Trab-MMC) in patients with angle-closure glaucoma (ACG).

42 Primary angle-closure glaucoma affects 20 million people worldwi

43 Angle-closure glaucoma after scleral buckling develops b

44 may present at an early age with features of angle closure glaucoma and a Thr518Met mutation in MYRF

45 Our patient demonstrated worsening angle closure glaucoma and choroidal detachments after s

46 ase represents the first report of worsening angle closure glaucoma and choroidal detachments over an

47 old Chinese female was diagnosed of primary angle closure glaucoma and had bilateral laser periphera

48 anophthalmos and pigmentary retinopathy with angle closure glaucoma and optic disc pit in one eye.

49 Clinically there was presence of bilateral angle closure glaucoma and peripheral choroidal detachme

50 Acute angle-closure glaucoma and a cataract with dilated iris

51 threatening condition, due to possible acute angle-closure glaucoma and maculopathy.

52 udies reporting on the prevalence of primary angle-closure glaucoma and other precursor forms of the

53 al eyes, presents a high risk for developing angle-closure glaucoma and related complications.

54 pressure (IOP) in patients with PAC, primary angle closure glaucoma, and acute angle closure crisis.

55 lems include endophthalmitis, macular folds, angle-closure glaucoma, and macular hole.

56 syndrome predisposes to both open-angle and angle-closure glaucoma, and to capsular rupture, zonular

57 The IOP reductions obtained in patients with angle closure glaucoma are often more pronounced than th

58 Topiramate has been reported to induce acute angle closure glaucoma as an adverse effect.

59 Women are at higher risks for angle closure glaucoma, but there is no clear gender pre

60 CG) eyes, 40 fellow eyes of AACG, 42 chronic angle-closure glaucoma (CACG) eyes, 40 primary angle-clo

61 of glaucoma reside in Asia, and with primary angle-closure glaucoma carrying a higher rate of visual

62 an origin have a higher frequency of primary angle-closure glaucoma compared with those of European o

63 ry angle closure (CPAC), and chronic primary angle closure glaucoma (CPACG).

64 nd significant visual comorbidities, such as angle closure glaucoma, cystic macular edema, and exudat

65 Patients with AAC/primary angle closure glaucoma diagnosis before the first dilati

66 eudophakia, ANA treatments, or prior primary angle closure glaucoma diagnosis.

67 The DBA/2J mouse is a model for secondary angle-closure glaucoma, due to iris atrophy and pigment

68 Acute angle-closure glaucoma emerged as the most frequently ob

69 , GAS7, FOXC1, ATXN2, TXNRD2); PACG (primary angle-closure glaucoma (EPDR1, CHAT, GLIS3, FERMT2, DPM2

70 An acute attack of angle-closure glaucoma following pupil dilation in regre

71 ulcers of 1 year's duration developed acute angle-closure glaucoma following the appearance of new m

72 Initial diagnoses included angle-closure glaucoma (four patients), Best disease (th

73 s and knowledge of retinal detachment, acute angle-closure glaucoma, giant cell arteritis, and centra

74 d definitions to detect and diagnose primary angle-closure glaucoma has resulted in difficulties in i

75 t surgery in patients with acute and chronic angle-closure glaucoma have been well studied and are ge

76 International investigations into primary angle-closure glaucoma have demonstrated reproducible ev

77 GWAS of primary angle-closure glaucoma have identified eight loci confer

78 oma--primary open-angle glaucoma and primary angle-closure glaucoma--have different risk factors.

79 ary glaucoma (HR = 1.641, P = .004), primary angle closure glaucoma (HR = 1.611, P < .001), and previ

80 (HR 0.755, 95% CI 0.729, 0.781) and primary angle-closure glaucoma (HR 0.702, 95% CI 0.636, 0.781).

81 removal surgery included presence of chronic angle-closure glaucoma (HR = 1.32; P < .001) and dry eye

82 e glaucoma (HR, 1.33; 95% CI, 1.16-1.52) and angle-closure glaucoma (HR, 1.66; 95% CI, 1.20-2.30).

83 ngs into discussion a new clinical entity of angle closure glaucoma in nanophthalmos accompanied by o

84 lmos with Optic Disc pit, with an associated angle closure glaucoma in the same eye, an association w

85 To report clinical features of bilateral angle-closure glaucoma in a patient with nanophthalmic e

86 the mechanism and natural history of primary angle-closure glaucoma in Asian populations.

87 He was previously diagnosed with angle-closure glaucoma in association with ocular cystin

88 pheral iridotomy prophylaxis against primary angle-closure glaucoma in Chinese people classified as p

89 s on the incidence and prevalence of primary angle-closure glaucoma in different ethnic groups.

90 ere, we present a discovery GWAS for primary angle-closure glaucoma in Europeans using the UK Biobank

91 cause of severe keratouveitis, cataract and angle-closure glaucoma in newborns.

92 The risk of angle-closure glaucoma in patients younger than 50 years

93 for a retina check-up could result in acute angle-closure glaucoma in ROP patients.

94 because of corneal decompensation in one and angle-closure glaucoma in the other.

95 Acute primary angle closure glaucoma is a potentially blinding ophthal

96 doplasty for long-term prevention of primary angle closure glaucoma is undetermined.

97 nanophthalmos and other conditions in which angle-closure glaucoma is a feature.

98 Primary angle-closure glaucoma is a leading cause of irreversibl

99 Primary angle-closure glaucoma is a major cause of irreversible

100 Canine hereditary angle-closure glaucoma is characterized by a progressive

101 tumumab use with ocular events such as acute angle-closure glaucoma, myopic shift, and choroidal effu

102 NTG: aHR, 1.87, 95% CI, 1.09-3.18), whereas angle-closure glaucoma (N = 3150) showed no significant

103 2 with IOP higher than 35 mm Hg, and 1 with angle-closure glaucoma not attributed to the study drug

104 Twelve affected family members had angle-closure glaucoma or occludable anterior-chamber an

105 primary open-angle glaucoma, chronic primary angle-closure glaucoma or pseudoexfoliation glaucoma wer

106 Angle closure glaucoma (OR=0.85), secondary glaucoma (OR

107 glaucoma (OR=1.11; P = .01) but not primary angle closure glaucoma (P = .87).

108 ding open-angle glaucoma (P = 0.36), chronic angle closure glaucoma (P = 0.85) and OHT (P = 0.42).

109 pseudoexfoliative glaucoma (PXG) and Primary Angle Closure Glaucoma (PACG) are scarce in the Sub-Saha

110 imary open angle glaucoma (POAG) and primary angle closure glaucoma (PACG) in a North Indian Punjabi

111 on the morbidity and progression to primary angle closure glaucoma (PACG) in White Caucasian individ

112 Primary angle closure glaucoma (PACG) is a major cause of blindn

113 Primary angle closure glaucoma (PACG) is a significant cause of

114 mary open angle glaucoma (POAG), 132 primary angle closure glaucoma (PACG) patients and 424 matched c

115 pen angle glaucoma (POAG), 27 (4.2%) primary angle closure glaucoma (PACG), and 5 (0.8%) normal tensi

116 with primary angle closure (PAC) and primary angle closure glaucoma (PACG), and to compare their diag

117 Glaucoma, particularly primary angle closure glaucoma (PACG), is a leading cause of glo

118 investigate whether the addition of primary angle closure glaucoma (PACG)-associated genetic loci al

119 imary open angle glaucoma (POAG) and primary angle closure glaucoma (PACG)] patients and matched heal

120 low-up examination, 5298 at risk for primary angle-closure glaucoma (PACG) and 5060 at risk for PACD

121 s and TIMPs in the aqueous humour of primary angle-closure glaucoma (PACG) eyes were measured and com

122 imary open-angle glaucoma (POAG) and primary angle-closure glaucoma (PACG) eyes.

123 with primary angle closure (PAC) or primary angle-closure glaucoma (PACG) in both eyes.

124 oth or acute angle closure [AAC]) or primary angle-closure glaucoma (PACG) over 5 years.

125 laucomatous VF loss in patients with primary angle-closure glaucoma (PACG) using pointwise linear reg

126 POAG), 0.39% (95% CI, 0.34-0.45) for primary angle-closure glaucoma (PACG), and 0.15% (95% CI, 0.07-0

127 imary open-angle glaucoma (POAG) and primary angle-closure glaucoma (PACG), and projected the number

128 s of visual field (VF) defects among primary angle-closure glaucoma (PACG), high-tension glaucoma (HT

129 SL), and trabectome in patients with primary angle-closure glaucoma (PACG).

130 Glaucoma cases were classified as primary angle-closure glaucoma (PACG); 1 of the 4 forms of open-

131 rmal-tension glaucoma [NTG], 1.5%]), primary angle-closure glaucoma (PACG, 0.4%), pseudoexfoliation g

132 Primary angle-closure glaucoma patients with 5 or more reliable

133 foliative glaucoma (PXG) and primary chronic angle closure glaucoma (PCAG) patients was 19.22 mmHg, 2

134 itional features can include microphthalmia, angle-closure glaucoma, persistent hyperplastic primary

135 cus associated with nanophthalmos or with an angle-closure glaucoma phenotype, and the identification

136 our understanding of the pathophysiology of angle-closure glaucoma, pigmentary glaucoma, and a varie

137 g a higher rate of visual morbidity, primary angle-closure glaucoma poses an important public health

138 70-year-old female with a history of primary angle closure glaucoma presented with 4 mm of proptosis,

139 spectrum of RP by presenting with bilateral angle-closure glaucoma prior to typical cartilage involv

140 ts with primary open-angle glaucoma, primary angle-closure glaucoma, pseudoexfoliative glaucoma, and

141 eful in the clinical management of eyes with angle closure glaucoma, recent studies show that the dec

142 f the first reported cases of severe chronic angle- closure glaucoma secondary to ciliary body cysts

143 ic and surgical management of severe chronic angle- closure glaucoma secondary to ciliary body cysts

144 odigital dysplasia, with progressive chronic angle- closure glaucoma secondary to ciliary body cysts

145 primary open-angle glaucoma (POAG), primary angle-closure-glaucoma, secondary glaucoma, or a combina

146 the development of angle-closure and primary angle-closure glaucoma should also be investigated.

147 mice develop a progressive form of secondary angle-closure glaucoma that appears to be initiated by i

148 suspect, primary angle closure, and primary angle closure glaucoma was 8.8 (8.4, 9.2), 6.2 (5.9, 6.6

149 Primary angle-closure glaucoma was 3 times more common in women.

150 9; 1.28-1.50, respectively), whereas primary angle-closure glaucoma was associated with VaD (1.26; 1.

151 Drugs associated with reports of angle-closure glaucoma were identified in FAERS through

152 angle glaucoma, normal-tension glaucoma, and angle-closure glaucoma were included.

153 Eligible patients had primary open-angle or angle-closure glaucoma, were aged >=18 years, and underw

154 he highest cost category among patients with angle-closure glaucoma, whereas office visits was the hi

155 We examined the risk of angle-closure glaucoma with bupropion hydrochloride, a u

156 erfluoropropene (C3F8) may produce secondary angle-closure glaucoma with or without pupillary block.